2024
A gap analysis of UK biobank publications reveals SNPs associated with intrinsic subtypes of breast cancer
van den Driest L, Kelly P, Marshall A, Johnson C, Lasky-Su J, Lannigan A, Rattray Z, Rattray N. A gap analysis of UK biobank publications reveals SNPs associated with intrinsic subtypes of breast cancer. Computational And Structural Biotechnology Journal 2024, 23: 2200-2210. PMID: 38817965, PMCID: PMC11137368, DOI: 10.1016/j.csbj.2024.05.001.Peer-Reviewed Original ResearchBreast cancerUK Biobank dataBreast cancer researchPatient stratificationVariants associated with breast cancerGenetic variants associated with breast cancerIntrinsic subtypes of breast cancerBiobank dataDied of breast cancerPrediction of tumor behaviorSubtypes of breast cancerProfiling of breast cancerPrognosis of breast cancerMeta-analysisBreast cancer subtypesImprove patient stratificationAnalysis of metabolomicsBreast cancer genesUK Biobank studyUK Biobank cohortAnalysis of breast cancerAnalysis of UK Biobank dataGlobal cancer burdenBreast cancer diagnosisCancer research
2022
Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets
Alnoumas L, van den Driest L, Apczynski Z, Lannigan A, Johnson CH, Rattray NJW, Rattray Z. Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets. BMC Cancer 2022, 22: 874. PMID: 35948941, PMCID: PMC9364282, DOI: 10.1186/s12885-022-09969-4.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisBreast cancerCancer prognosisFemale cancer-related mortalityPoor patient survival outcomePrecision medicine-based approachKPNA2 overexpressionNovel chemotherapy agentsCancer-related mortalityPatient survival outcomesPoor patient prognosisAggressive tumor phenotypePatient agePrognostic rolePatient survivalSurvival outcomesPatient prognosisLeading causeChemotherapy agentsClinical dataCancer casesClinicopathologic parametersPatient stratificationActionable targetsChemotherapy resistance
2018
Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy
Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, Benton HP, Goetz L, Johnson CH, Siuzdak G. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology 2018, 25: 291-300.e3. PMID: 29337187, PMCID: PMC5856613, DOI: 10.1016/j.chembiol.2017.12.010.Peer-Reviewed Original ResearchConceptsEffects of palbociclibPositive breast cancerUS FDA approvalGlobal metabolomics approachMCF-7 cellsCombination therapyBreast cancerEstrogen receptorMetabolic effectsPhytoestrogen genisteinFDA approvalModel xenoestrogenCellular metabolismCancer therapyFunctional assaysXenoestrogensPathway modificationTherapyMetabolomics approachCombination cancer therapyFatty acidsEstrogenic mycotoxin zearalenoneProliferation experimentsMetabolitesMetabolism